IE 11 is not supported. For an optimal experience visit our site on another browser.

Revolutions Medical Places Initial Production Order of 2.5 Million Syringes

CHARLESTON, S.C., April 7, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCQB:RMCP) announces today the completion of its pre-production obligations under its manufacturing agreement with Medical Investment Group, LLC ("MIG"). The Company recently placed its first order for 2.5 million 3ml RevVac™ Auto Retractable Vacuum Safety Syringes (the "RevVac™ Safety Syringe"). This initial order will begin to fulfill commitments made to distributors since the introduction of the RevVac™ Safety Syringe during the November 2010 Medica Conference in Dusseldorf, Germany. The Company anticipates this order to be shipped and delivered during the current quarter of 2011.
/ Source: GlobeNewswire

CHARLESTON, S.C., April 7, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCQB:RMCP) announces today the completion of its pre-production obligations under its manufacturing agreement with Medical Investment Group, LLC ("MIG"). The Company recently placed its first order for 2.5 million 3ml RevVac™ Auto Retractable Vacuum Safety Syringes (the "RevVac™ Safety Syringe"). This initial order will begin to fulfill commitments made to distributors since the introduction of the RevVac™ Safety Syringe during the November 2010 Medica Conference in Dusseldorf, Germany. The Company anticipates this order to be shipped and delivered during the current quarter of 2011.

"The Company has reached a significant milestone this week by placing an initial order for our RevVac™ Safety Syringe and finally bringing it to the marketplace. I am very proud to have what I feel is the best safety syringe in the world now available to health care workers. I look forward to an onsite visit at the factory in China next week and seeing our syringes being produced," states Ron Wheet, CEO and Chairman, Revolutions Medical Corporation.

The RevVac™ Safety Syringe uses advanced vacuum proprietary technology. After injected into the patient, the needle itself is safely retracted into the barrel of the syringe.  The vacuum retraction technology employed by the RevVac™ Safety Syringe is instantaneous and automatic, requiring no activation by the user. The vacuum safety feature cannot be deactivated and protects and conceals the needle through final disposal. The RevVac™ Safety Syringe's easy to use, one-handed procedure will virtually eliminate the possibility of accidental needle sticks with proper use. Because of the RevVac™ Safety Syringe's design, the footprint for hazardous waste disposal is much smaller, thereby creating additional cost savings on top of being priced significantly lower than its competition.

MIG's manufacturing facility is a 250,000 square foot factory located on 35 acres in Jiangsu, China. The factory is fully compliant with all FDA and CE/EC requirements and has extensive experience producing and shipping similar medical products for worldwide delivery. The factory currently operates 20 sets of injection molding machines along with several units of ethylene oxide sterilizer and testing equipment for optimal quality compliance. In 2007, the factory implemented the ISO13485 standard and has passed each annual review since.

About Revolutions Medical Corporation

Revolutions Medical is a safety medical device and software application company. Its products include the RevVac™ Safety Syringe (FDA cleared), safety blood drawing device, the RevColor™, RevDisplay™ and Rev3D™ software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS), preliminary called RevTrack (FDA cleared).

For additional information, please visit Revolutions Medical corporate website:

To be added to the Revolutions Medical investor email list, please email: investment@revolutionsmedical.com with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook – visit:

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACT: Revolutions Medical Corporation Investor and Corporate Relations Gregory S. Lowe Acorn Management Partners President / Partner 678-368-4013